Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (211-220 of 244) with videos related to

Pageof 25
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Nature Communications|September 23, 2022
Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infectionElham Khatamzas, Markus H Antwerpen, Alexandra Rehn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell TherapyConrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Cell Reports. Medicine|November 17, 2022
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphomaJohannes F Fahrmann, Neeraj Y Saini, Chang Chia-Chi, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood Neoplasia|August 1, 2025
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemiaMartin Hutchings, Koorosh Korfi, Pau Montesinos, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 25

Showing results (211-220 of 244) with videos related to

Sort By:
Pageof 25
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Nature Communications|September 23, 2022
Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infectionElham Khatamzas, Markus H Antwerpen, Alexandra Rehn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell TherapyConrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Cell Reports. Medicine|November 17, 2022
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphomaJohannes F Fahrmann, Neeraj Y Saini, Chang Chia-Chi, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood Neoplasia|August 1, 2025
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemiaMartin Hutchings, Koorosh Korfi, Pau Montesinos, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 25